[Radioimmunoassays in oncology]
- PMID: 6189774
[Radioimmunoassays in oncology]
Abstract
Aside from imaging techniques several (radio-)immunological analyses are used for tumor diagnosis. Oncofetal antigens, for instance the carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP), have become the most important substances for many malignancies. However, nearly all of the so-called tumor markers are not suitable for early diagnosis or screening either because of low sensitivity or low tumor specificity. On the other hand follow-up measurements give a very sensitive index of the success of treatment and may indicate tumor progression when other signs are still not present. In some carcinomas and under some clinical circumstances tumor specific markers are available and mandatory for detection and/or staging: AFP in hepatoma, acid phosphatase in metastasizing carcinoma of the prostate and serum thyreoglobulin in differentiated thyroid cancer.
Similar articles
-
Overview of oncofetal antigens in cancer.Ann Clin Lab Sci. 1983 Jul-Aug;13(4):261-6. Ann Clin Lab Sci. 1983. PMID: 6194734
-
[Sense and nonsense of tumor markers in practice].Schweiz Med Wochenschr. 1990 May 12;120(19):693-703. Schweiz Med Wochenschr. 1990. PMID: 1693445 Review. German.
-
Oncofetal antigens. Increasing the specificity of the CEA radioimmunoassay.Am J Clin Pathol. 1977 Nov;68(5 Suppl):679-87. Am J Clin Pathol. 1977. PMID: 72501
-
[Oncofetal proteins - their character and clinical significance as tumour-markers (author's transl)].Zentralbl Chir. 1980;105(23):1537-45. Zentralbl Chir. 1980. PMID: 6163265 German.
-
Advances in the use of tumor markers.Compr Ther. 1990 Nov;16(11):51-7. Compr Ther. 1990. PMID: 1702695 Review. No abstract available.